The role of higher education institutions for entrepreneurship stimulation in the regional innovation systems: evidence from the network-oriented EXIST: promotion of university-based start-ups programme in Germany

K. Koschatzky

Abstract:ISSN 1438-9843 * This is the full version of a paper presented at the workshop "The influence of co-operations, networks and institutions on regional innovation systems",

What problem does this paper attempt to address?

The full range of ophthalmological clinical manifestations in systemic lupus erythematosus

Nikita Kedia,Vincent Theillac,Manuel Paez-Escamilla,Chad Indermill,Denise S Gallagher,Raphaël Adam,Anne Lise Qu-Knafo,Fatima Amari,Caroline Bottin,Géraldine Chotard,Violaine Caillaux,Maté Strého,Neila Sedira,Emmanuel Héron,Pierre-André Becherel,Bahram Bodaghi,Sarah Mrejen-Uretski,Alain-José Sahel,David Saadoun,Marie-Hélène Errera

DOI: https://doi.org/10.3389/fopht.2022.1055766

2023-01-26

Abstract:Purpose: To determine the full range of ophthalmological clinical manifestations in systemic lupus erythematosus (SLE) and to compare the systemic features associated with them. Methods: Files of 13 patients with ocular SLE (n = 20 eyes) diagnosed as per the American College of Rheumatology (ACR) 2012 revised criteria were retrospectively reviewed. Results: The following clinical manifestations were found: keratoconjunctivitis sicca (n = three patients), anterior uveitis associated with an inflammatory pseudo-tumor orbital mass (n = one patient, one eye), episcleritis and periorbital edema (n = one patient, two eyes), posterior scleritis (n = one patient, two eyes), bilateral papillary edema in the context of idiopathic intracranial hypertension (n = one patient, one eye), inflammatory optic neuritis (n = one patient, one eye), and lupus retinopathies with varying degrees of capillary occlusions mainly arteriolar (n = seven patients, 13 eyes) and larger arteries or veins (retinal arteries occlusions and retinal veins occlusions) (n = one patient, two eyes). Some patients presented with combined ophthalmological manifestations.Systemic SLE was discovered by its ophthalmic manifestation in three cases (23%) and was previously known in the other 10 cases (77%). On average, ocular symptoms were seen 8 years after the initial diagnosis of SLE. Other systemic SLE disorders included cutaneous disorders (77%), joint disorders (38%), central nervous system (CNS) disorders (23%), renal disorders (38%), and oral ulcers (23%).Treatment of the ophthalmic system manifestations of lupus included local steroid therapies along with systemic immunosuppression.The most common laboratory ACR criteria were: high levels of antinuclear antibodies (ANA) (100%), positive anti-Sm (64%), anti-dsDNA (27%), low complement levels (27%), and positive antiphospholipid (APL) antibodies (18%). Discussion: SLE activity in the ophthalmic system is characterized by its functional severity and the range of involvement can be categorized by anatomical involvement: presence of anterior uveitis, episcleritis, scleritis, periorbital edema, posterior uveitis with retinal vascular ischemia, or papillary edema. Not currently part of the diagnosis criteria of the SLE ACR given its rarity, the ocular localization of the pathology led to the diagnosis of SLE in three cases; thus, developing a greater understanding of ocular lupus may help in identifying and treating systemic manifestations of lupus earlier.
Drug-induced maculopathy.

J. Kempen

DOI: https://doi.org/10.1097/00004397-199903940-00007

International Ophthalmology Clinics

Abstract:
[Ocular manifestations in patients with systemic lupus erythematosus and antiphospholipid syndrome]

Lidia Ostanek,Monika Modrzejewska,Danuta Bobrowska-Snarska,Marek Brzosko

Abstract:Introduction: Systemic lupus erythematosus (SLE) is a systemic disease of connective tissue with broad band of symptoms. It could be the reason for many organs and tissues impairment. Changes in eyes that occurr in SLE are not frequent, but can lead to severe impairment of sight including blindness. Objectives: The aim of the work was to asses the frequency of eye changes among patients with SLE and SLE with antiphospholipid syndrome (APS). Another aim was to asses the association between antiphospholipid antibodies and ocular lesions. Patients and methods: There were 75 patients enrolled with SLE, 26 of them ha APS. All of patients had a comprehensive ophthalmological and physical examination. Moreover biochemica analysis including lipid profile and glucose metabolism and serological markers of APS and SLE were performe Results: Thirty-six patients complained of ophthalmologic disturbances (48%), with "dry eyes" being the most common symptom (20 patients). The reduced visual acuity was detected in 17 patients (22.6%). Conjunctivitis was found in 8 patients (10.67%), corneal involvement in 31 (41.3%), and sclera changes in 40 patients (53.3%). Changes in retina were found in 15 (20%) of patients, the most frequent were sub-retinal edema in the region of yellow spot. Changes in yellow spot were found in 8 patients; in 2 of them it was associated with dry degenerative changes, in 6 patients exudates with or without hemorrhages were found. Vascular changes including their lumen diameter were found in 33 patients (44%). In 4 patients there were changes in optical nerve disc. Schirmer's test was pathological in 43 patients (57.3%), but in only 4 patients Sjögren's syndrome was diagnosed. In the group of SLE patients intraocular pressure was significantly higher. The presence of anticardiolipin antibodies IgG class (aCL IgG) was associated with reduced visual acuity. The presence of lupus anticoagulant and anti-beta2, glycoprotein-I antibodies (anti-beta2GPI) was associated with conjunctive involvement. The presence of aCL IgM and anti-beta2GPI was associated with less frequent symptoms of eye dryness. Conclusions: We found the following significant factors of the occurrence of eye involvement in our series of SLE patients: high activity of disease (conjuctiva, iris, uvea, retina, spot, vessels and optical nerve disc involvement), late diagnosis of SLE (retinopathy and conjuctive involvement), arterial hypertension (reduced visual acuity, cornea involvement, vessels involvement), age (reduced visual acuity, cornea involvement, retinopathy), glucose metabolism disorders (changes in optical nerve disc) and presence of anti-double stranded DNA antibodies (retinopathy).
Responsive self-assembled nanostructured lipid systems for drug delivery and diagnostics.

W. Fong,Renata Negrini,Jijo J. Vallooran,R. Mezzenga,B. Boyd

DOI: https://doi.org/10.1016/j.jcis.2016.08.077

IF: 9.9

2016-12-15

Journal of Colloid and Interface Science

Abstract:
Detection and Localization by In Situ Molecular Biology Techniques and Immunohistochemistry of Hepatitis C Virus in Livers of Chronically Infected Patients

Francine Walker,M. Dazza,M. Dauge,O. Boucher,Christophe Bedel,D. Henin,T. Lehy

DOI: https://doi.org/10.1177/002215549804600510

1998-05-01

Abstract:Hepatitis C virus (HCV) detection in the livers of chronically infected patients remains a debatable issue. We used immunohistochemistry, in situ hybridization (ISH) alone or after microwave heating with FITC-labeled probes, RT-PCR with unlabeled primers followed by ISH (RT-PCR-ISH), and in situ RT-PCR with FITC-labeled primers (in situ RT-PCRd) to localize the virus in 38 liver biopsy specimens from 21 chronically infected HCV patients treated with interferon-α (IFN-α). Biopsies were taken at the beginning and end of IFN-α treatment and 1 year later. Results were compared with that of HCV-PCR in serum. RT-PCR-ISH and in situ RT-PCRd showed HCV signal in all liver biopsies even in responders with seronegative HCV PCR. This signal was intranuclear, diffuse, or peripheral, in hepatocytes, bile ductule cells, and lymphocytes. Cytoplasmic signals were occasionally observed. Whereas the percentage of labeled hepatocytes remained constant, the number of labeled lymphoid follicles decreased after INF-α therapy. Immunohistochemistry resulted in the same pattern of positivity but it was weaker and inconstant. This study indicates the persistency of HCV latency in IFN-α responders 1 year after IFN-α treatment cessation, a finding that certainly deserves confirmation.
Systemic lupus erythematosus and ocular involvement: an overview

Rosanna Dammacco

DOI: https://doi.org/10.1007/s10238-017-0479-9

Abstract:Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease of undefined etiology and with remarkably heterogeneous clinical features. Virtually any organ system can be affected, including the eye. SLE-related eye involvement can be diagnosed in approximately one-third of the patients and is usually indicative of disease activity. An early diagnosis and the adoption of suitable therapeutic measures are necessary to prevent sight-threatening consequences, especially in patients with juvenile SLE. Periocular lesions, such as eyelid involvement and orbital inflammation, are relatively rare and, in case of orbital masses, may require a biopsy control. Keratoconjunctivitis sicca or secondary Sjögren's syndrome is the most frequent ophthalmic manifestation of SLE. According to its variable severity, lubricating tear drops may be sufficient in mild cases, whereas cyclosporine-A ophthalmic solution, glucocorticoids (GCs), methotrexate, and/or other immunosuppressive drugs may be required in the more severe cases. Partial occlusion of the lacrimal punctum by thermal cautery is rarely applied. Although uncommon, episcleritis and scleritis can sometimes be detected as an initial finding of SLE and reveal themselves as moderate to intense ocular pain, redness, blurred vision, and lacrimation. Unilateral or more often bilateral retinopathy is responsible for visual loss of variable severity and is ascribed to vasculitis of the retinal capillaries and arterioles. In addition to the combined treatment suitable for all patients with active SLE, intravitreal bevacizumab should be considered in cases of severe vaso-occlusive retinopathy and laser photocoagulation in cases of neovascularization. Purtscher-like retinopathy is likely ascribable to the formation of microemboli that results in retinal vascular occlusion and microvascular infarcts. Choroidal disease is characterized by monolateral or bilateral blurred vision. Because of the choroidal effusion, retinal detachment and secondary angle-closure glaucoma may occur. Ischemic optic neuropathy is characterized by acute-onset and progressive binocular visual impairment as a consequence of occlusion of the small vessels of the optic nerves due to immune complex vasculitis. Intravenous GC boluses followed by oral GCs and/or, in case of recurrence, intravenous cyclophosphamide and/or rituximab are commonly employed. Neovascularization can be treated by intravitreal bevacizumab and progression of retinal ischemic areas by retinal laser photocoagulation. Ocular adverse events (AE) have been described following the long-term administration of one or more of the drugs presently used for the treatment of SLE patients. Posterior subcapsular cataracts and secondary open-angle glaucoma are common AE of the prolonged GC administration. The long-term administration of hydroxychloroquine (HCQ) sulfate is well known to be associated with AE, such as vortex keratopathy and in particular the often irreversible and sight-threatening maculopathy. Length of administration > 5 years, > 1000 g total HCQ consumption, > 6.5 mg/kg daily dosing, coexistence of renal disease, and preexisting maculopathy are all considered risk factors for HCQ-induced retinopathy. Ocular AE of additional immunosuppressive and biological agents are still poorly known, given the worldwide more limited experience with their long-term use. A thorough ophthalmological control is strongly recommended at closer intervals for all SLE patients, in step with the total length of exposure to the drugs and the cumulative dose administered.
Preemptive ganciclovir therapy in renal transplantation.

D. Brennan,G. Storch,B. Lippman

IF: 39.2

Annals of Internal Medicine

Abstract:
Influence of wholesale lamb marketing options and merchandising styles on retail yield and fabrication time.

C. Lorenzen,A. M. Martín,D. Griffin,T. Dockerty,J. P. Walter,H. Johnson,J. Savell

DOI: https://doi.org/10.2527/1997.7511

Journal of Animal Science

Abstract:Lamb carcasses (n = 94) from five packing plants, selected to vary in weight class and fat thickness, were used to determine retail yield and labor requirements of wholesale lamb fabrication. Carcasses were allotted randomly according to weight class to be fabricated as whole carcasses (n = 20), three-piece boxes (n = 22), or subprimals (n = 52). Processing times (seconds) were recorded and wholesale and retail weights (kilograms) were obtained to calculate retail yield. Subprimals were fabricated into bone-in retail cuts or boneless or semi-boneless retail cuts. Retail yield for subprimal lamb legs decreased from 85.3 +/- .6% for bone-in to 68.0 +/- .7% for a completely boneless retail product. Correspondingly, processing times increased from 126.1 +/- 5.4 s to 542.0 +/- 19.2 s for bone-in and boneless legs, respectively. For all subprimals, retail yield percentage tended to decrease and total processing time increase as cuts were fabricated to boneless or semi-boneless end points compared with a bone-in end point. Percentage retail yield did not differ (P > .05) among whole carcass, three-piece box, and subprimal marketing methods. Total processing time was shorter for subprimals (P < .05) than for the other two marketing methods.
Ocular Involvement in Systemic Lupus Erythematosus: The Experience of Two Tertiary Referral Centers

Rosanna Dammacco,Pasquale Procaccio,Vito Racanelli,Angelo Vacca,Franco Dammacco

DOI: https://doi.org/10.1080/09273948.2018.1501495

Abstract:Purpose: To assess the prevalence of the ocular manifestations related to the disease and/or ascribable to the administration of potentially toxic drugs in a cohort of 98 patients with systemic lupus erythematosus (SLE). Methods: Retrospective, observational study reporting the experience of two tertiary referral centers. Results: Overall, an ocular involvement was detected in 29 patients (29.6%), sometimes preceding of months the diagnosis of SLE, more often revealed at diagnosis or throughout its course. More than a single ocular manifestation was found in 20 of the 29 patients with ophthalmological findings (68.9%). The array of ocular morbidity included, in a decreasing order of frequency, cataracts, keratoconjunctivitis sicca, glaucoma, discoid lesions of eyelids, episcleritis, retinopathy, vortex keratopathy, choroidopathy and retinal detachment, central retinal vein occlusion, and hydroxychloroquine-induced toxic maculopathy. Conclusions: It is advised that a multidisciplinary team for the diagnosis and treatment of SLE should regularly include the presence of an ophthalmologist.
Thermal dose and time-temperature factors for biological responses to heat shock.

E. Gerner

DOI: https://doi.org/10.3109/02656738709140402

1987-07-01

International Journal of Hyperthermia

Abstract:The application of hyperthermia in human cancer therapy, especially by radiotherapists who are accustomed to prescribing ionizing radiation treatments in physical dose units, has stimulated workers in this area to consider the possibility and utility of defining a unit of 'thermal dose'. Previous thermal dose definitions have, primarily, been based on biological isoeffect response relationships, which attempt to relate exposure times that elicit a given biological response at one temperature to exposure times at another temperature that elicit the same biological response. This 'equivalent time' method is shown to have certain limitations. For both 42.4 and 45 degrees C hyperthermia, these relationships accurately describe cell survival responses only when the heating rate is rapid (greater than 0.5 degrees C min-1 from ambient to hyperthermic temperature). Further, the form of these isoeffect relationships appears to be temperature range and cell/tissue-type dependent, and it is suggested that these relationships be referred to as a 'time-temperature factor' (TTF) to help distinguish them from possible physical thermal dose definitions. Two physical dose definitions are discussed, one being simply exposure time at some temperature and the other being a more fundamental definition, the free energy change which is a temperature-dependent driving force for chemical reactions.
Ocular manifestations of systemic lupus erythematosus in children

Sulaiman M Al-Mayouf,Amal I Al-Hemidan

Abstract:Objective: To determine the prevalence and spectrum of ocular manifestations in children with systemic lupus erythematosus (SLE) and to examine the correlation of the ocular manifestations with disease activity, other organ involvement and the presence of circulating autoantibodies. Methods: In this cross-sectional study, we performed at King Faisal Specialist Hospital and Research Centre, Riyadh, Kingdom of Saudi Arabia from June 2000 to November 2002, a comprehensive evaluation including detailed eye examination, measuring circulating autoantibodies (antinuclear, antiphospholipid antibodies) and calculation of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Results: Fifty-two consecutive children (45 females) with SLE completed the evaluation. The mean age of the patients was 11.3 years and the mean SLEDAI was 9.5. Thirty patients (57.7%) had the disease for more than one year. Eighteen patients (34.6%) had ocular manifestations. Seven patients had abnormal Schirmer s test (2 bilateral, 5 unilateral). Five patients had (4 unilateral, one bilateral) retinal vascular lesions. One patient had bilateral iridocyclitis. Three patients had unilateral optic neuropathy and 11 patients had visual field defects (4 bilateral, 7 unilateral). Fisher exact test revealed positive correlation between optic neuropathy and central nervous system (CNS) involvement (p<0.002). There was no correlation among other variables; probably due to the sample size. Conclusion: Ocular manifestations including sight threatening complications are not rare in children with SLE. Optic neuropathy has strong prediction for CNS lupus.
Exigency of ocular complications of systemic lupus erythematosus

P K Kaviarasan

DOI: https://doi.org/10.18231/j.ijced.2020.023

2020-06-15

IP Indian Journal of Clinical and Experimental Dermatology

Abstract:Systemic lupus erythematosus (SLE) is an auto immune connective tissue disease which affects all organs in the body including eye. Ocular manifestations vary with underlying severity of the SLE had beed observed in 30% of cases. Ocular complications of SLE are commonly seen in advanced but uncontrolled and patients on irregular treatment. Keratoconjunctivitis sicca is the most common form of ocular complication of SLE, clinically manifests as dry eyes, lack of tear production which can be managed with artificial tear preparations. Clinical severity varies from mild asymptomatic red eyes and acute painful conjunctivitis, retrobulbar pain, orbital cellulitis, retinal artery occlusion and very severe cases leads to blindness which is often irreversible. Scleritis is an inflammatory complication of sclera which is as common as episcleritis in SLE. It can be classified in to anterior scleritis and posterior scleritis. Retinal involvement is a rare devastating complication of SLE. The prevalence of retinal disease in SLE accounts for 10% of cases. Mild forms of retinopathy are usually asymptomatic. In acute cases of SLE, the retinal changes manifests as defects in the visual field, distortion or floaters and sudden loss of vision. Anti-inflammatory agents, corticosteroids, anti-malarials play a major role in the management of long-standing complications of SLE. Immune complex deposition of antibodies against various structures of eye manifest differently. Early suspicion, prompt treatment, periodic monitoring of disease activity, early ophthalmic assessment of fundus, retina will bring down the incidence of SLE associated blindness. Early intervention of immune complex mediated Vasculitis involving eyes will prevent brain stem and central Nervous system (CNS) complications will bring down the mortality.
[Asessment and measurement of psychosocial variables: a challenge for nursing research and attention].

Dalete Mota,Cibele A. M. Pimenta

2007-09-01

Revista Gaúcha de Enfermagem

Abstract:Assessment and measurement of psychosocial variables are challenging. These constructs are complex, and there is distrust as to the validity of using standardized instruments Jor their measurement. There is a large variety of instruments and much confusion regarding the terms used to describe the validity and reliability tests. This paper adopts the theoretical reference of psychometrics. Its purpose is to update knowledge on general and psychometric characteristics of instruments for the assessment of subjective phenomena, to establish a parallel between similar terms, and to present a guide for choosing instruments. The enhancement of measurement instruments will improve nursing research and attention.
Inside information: researching long-term breastfeeding.

S. Dowling

2009-12-01

Abstract:
Sensitization to bradykinin B1 and B2 receptor activation in UV-B irradiated human skin

H. Eisenbarth,R. Rukwied,M. Petersen,M. Schmelz

DOI: https://doi.org/10.1016/j.pain.2004.03.031

IF: 7.926

2004-07-01

Pain

Abstract:
Unveiling Ocular Manifestations in Systemic Lupus Erythematosus

Mutali Musa,Ekele Chukwuyem,Oluwasola Michael Ojo,Efioshiomoshi Kings Topah,Leopoldo Spadea,Carlo Salati,Caterina Gagliano,Marco Zeppieri

DOI: https://doi.org/10.3390/jcm13041047

IF: 3.9

2024-02-13

Journal of Clinical Medicine

Abstract:Systemic Lupus Erythematosus (SLE) is a complex autoimmune disorder characterized by immune dysregulation and multi-organ involvement. In this concise brief review, we highlight key insights into Ocular Systemic Lupus Erythematosus (SLE), an intricate autoimmune disorder with diverse organ involvement. Emphasizing the formation of autoantibodies and immune complex deposition, we delve into the inflammation and damage affecting ocular structures. Clinical presentations, ranging from mild dry eye syndrome to severe conditions like retinal vasculitis, necessitate a comprehensive diagnostic approach, including clinical exams, serological testing, and imaging studies. Differential diagnosis involves distinguishing SLE-related ocular manifestations from other autoimmune and non-inflammatory ocular conditions. The multidisciplinary management approach, involving rheumatologists, ophthalmologists, and immunologists, tailors treatment based on ocular involvement severity, encompassing corticosteroids, immunosuppressive agents, and biologics. Follow-up is crucial for monitoring disease progression and treatment response. Future perspectives revolve around advancing molecular understanding, refining diagnostic tools, and exploring targeted therapies. Novel research areas include genetic factors, microbiome composition, and biotechnology for tailored and effective SLE ocular treatments.

medicine, general & internal
Ocular fundus changes and association with systemic conditions in systemic lupus erythematosus

Lihui Meng,Yinhan Wang,Zhikun Yang,Shiqun Lin,Yuelin Wang,Huan Chen,Xinyu Zhao,Youxin Chen

DOI: https://doi.org/10.3389/fimmu.2024.1395609

IF: 7.3

2024-07-18

Frontiers in Immunology

Abstract:Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organs and systems. Ocular involvement is estimated to manifest in one-third of individuals with SLE, of which lupus retinopathy and choroidopathy represent the severe subtype accompanied by vision impairment. Advancements in multimodal ophthalmic imaging have allowed ophthalmologists to reveal subclinical microvascular and structural changes in fundus of patients with SLE without ocular manifestations. Both ocular manifestations and subclinical fundus damage have been shown to correlate with SLE disease activity and, in some patients, even precede other systemic injuries as the first presentation of SLE. Moreover, ocular fundus might serve as a window into the state of systemic vasculitis in patients with SLE. Given the similarities of the anatomy, physiological and pathological processes shared among ocular fundus, and other vital organ damage in SLE, such as kidney and brain, it is assumed that ocular fundus involvement has implications in the diagnosis and evaluation of other systemic impairments. Therefore, evaluating the fundus characteristics of patients with SLE not only contributes to the early diagnosis and intervention of potential vision damage, but also holds considerate significance for the evaluation of SLE vasculitis state and prediction of other systemic injuries.

immunology
Dry eye disease in systemic lupus erythematosus: a cross sectional study

Sui-Fang Kang,,Qi-Chen Zhang,Zhi-Lun Wang,Guo-Ling Chen,,,

DOI: https://doi.org/10.18240/ijo.2024.07.09

IF: 1.645

2024-07-18

International Journal of Ophthalmology

Abstract:AIM: To explore ocular surface manifestations of dry eye disease (DED) and its influencing factors in systemic lupus erythematosus (SLE) patients. METHODS: Ophthalmological examinations were conducted in SLE patients (n=43) and controls (n=41), including Ocular Surface Disease Index (OSDI), objective scatter index (OSI), tear meniscus height (TMH), lipid layer thickness (LLT), non-invasive Keratograph tear breakup time (NIKBUT), corneal fluorescein score (CFS), Schirmer I test. DED was diagnosed according to the Tear Film and Ocular Surface Society Dry Eye Workshop II Criteria. SLE patients were further divided into DED group and non-DED group, the disease activity, clinical manifestations and laboratory investigations were compared between the two groups. The disease activity was evaluated by Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). Receiver operative characteristic (ROC) curve and multiple-factor binary logistic regression were performed. RESULTS: SLE patients showed higher OSDI [9.1 (2.8-15.9) vs 6.3 (2.2-7.5), P=0.035], higher OSI [1.67 (1.09-2.60) vs 0.96 (0.87-1.60), P=0.001], higher CFS [1 (0-2) vs 0 (0-1), P=0.001], lower LLT [65 (42-100) vs 100 (79.5-100), P=0.010], and lower NIKBUT [8.03 (4.02-9.73) vs 9.67 (5.26-12.71), P=0.030] than controls. The 32.6% of SLE patients had DED, which was higher than 12.2% of healthy controls. DED group showed higher SLEDAI-2K score [9.7±6.1 vs 5.4±3.4, P=0.025], higher anti-cardiolipin antibody (ACL) [8.7 (3.5-13.2) vs 3.6 (2.0-6.9), P=0.035], and higher proportion of patients with cutaneous eruption [42.9% vs 6.9%, P=0.015] than non-DED group. According to multiple-factor binary logistic regression analysis, the SLEDAI-2K score (OR=1.194, P=0.041) and cutaneous eruption (OR=7.094, P=0.045) could be consider as risk factors for DED in SLE patients. The ROC curve of the combined factors including age, disease duration, SLEDAI-2K score, ACL, and cutaneous eruption was analyzed, with a sensitivity of 0.786, a specificity of 0.793, and an area under curve of 0.820. CONCLUSION: Ocular surface affection is frequent in SLE patients, and patients with high disease activity and cutaneous eruption show increased risk of DED.

ophthalmology
Ocular Complications in Cutaneous Lupus Erythematosus: A Systematic Review with a Meta-Analysis of Reported Cases

L Arrico,A Abbouda,I Abicca,R Malagola

DOI: https://doi.org/10.1155/2015/254260

Abstract:Ocular complications associated with cutaneous lupus erythematosus (CLE) are less studied compared with those ones associated with systemic lupus erythematosus (SLE). The main ocular sites involved in patients affected by discoid lupus erythematosus (DLE) are eyelids followed by orbit and periorbit, the least being cornea. The most common complications are blepharitis usually affecting the lower lid and associated with some type of lid lesion such as plaque or erythematosus patches and madarosis. Few cases with LE profundus (LEP) and ocular complications are reported, but they are associated with orbital inflammatory syndrome and severe complications. The main treatment prescribed is hydroxychloroquine with a dose of 200 mg twice a day for 6 to 8 weeks. Corticosteroids are also used. Intervals between the correct diagnosis and the beginning of the ocular symptoms are commonly delayed. Ophthalmologist should be aware of the ocular manifestation of this autoimmune disease.
Various Ocular Manifestations in Systemic Lupus Erythematosus: A Case Series

Muhammad Hazim Sharum,Rajasudha Sawri Rajan,Tajunisah Iqbal

DOI: https://doi.org/10.7759/cureus.56503

2024-03-19

Cureus

Abstract:Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disorder with various systemic and ocular clinical manifestations. In patients with SLE, central retinal vein and artery occlusion, choroidopathy, and occlusive vasculitis are among the most significant and clinically relevant ocular manifestations, although they do not commonly occur. We present a case series of three SLE patients of different races and genders who developed ocular-related clinical features of SLE during the course of their systemic disease. The clinical outcomes of each patient were different, affecting their vision in bilateral eyes, with some patients having better visual recovery while others having permanently poor vision. These outcomes were not significantly related to the patients' age, gender, or race.

The role of higher education institutions for entrepreneurship stimulation in the regional innovation systems: evidence from the network-oriented EXIST: promotion of university-based start-ups programme in Germany

The full range of ophthalmological clinical manifestations in systemic lupus erythematosus

Drug-induced maculopathy.

[Ocular manifestations in patients with systemic lupus erythematosus and antiphospholipid syndrome]

Responsive self-assembled nanostructured lipid systems for drug delivery and diagnostics.

Detection and Localization by In Situ Molecular Biology Techniques and Immunohistochemistry of Hepatitis C Virus in Livers of Chronically Infected Patients

Systemic lupus erythematosus and ocular involvement: an overview

Preemptive ganciclovir therapy in renal transplantation.

Influence of wholesale lamb marketing options and merchandising styles on retail yield and fabrication time.

Ocular Involvement in Systemic Lupus Erythematosus: The Experience of Two Tertiary Referral Centers

Thermal dose and time-temperature factors for biological responses to heat shock.

Ocular manifestations of systemic lupus erythematosus in children

Exigency of ocular complications of systemic lupus erythematosus

[Asessment and measurement of psychosocial variables: a challenge for nursing research and attention].

Inside information: researching long-term breastfeeding.

Sensitization to bradykinin B1 and B2 receptor activation in UV-B irradiated human skin

Unveiling Ocular Manifestations in Systemic Lupus Erythematosus

Ocular fundus changes and association with systemic conditions in systemic lupus erythematosus

Dry eye disease in systemic lupus erythematosus: a cross sectional study

Ocular Complications in Cutaneous Lupus Erythematosus: A Systematic Review with a Meta-Analysis of Reported Cases

Various Ocular Manifestations in Systemic Lupus Erythematosus: A Case Series